Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Complement c5 inhibitors
13 evidence topics · 14 sources
Eculizumab in refractory AChR antibody-positive disease: 2020 consensus update
“In a phase III international multicenter RCT of 125 patients with refractory generalized nonthymomatous AChR-Ab+ MG (REGAIN), the primary outcome measure of change in the MG-ADL score from baseline to week 26, measured by worst-rank analysis of covariance, was not significantly different ( p = 0.0698) between eculizumab and placebo arms.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Eculizumab should be considered in the treatment of severe, refractory, AChR-Ab+ generalized MG (median 9, range 2–9). The role of eculizumab in the treatment of MG is likely to evolve over time. Until further data become available to allow comparisons of cost and efficacy with other treatments, eculizumab should be considered after trials of other immunotherapies have been unsuccessful in meeting treatment goals (median 9, range 5–9).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Complement inhibitors and FcRn blockers as second-line treatments: Nordic guidance
“Several inhibitors of complement proteins have appeared within the last 5 years as a new treatment modality for refractory or difficult‐to‐treat MG patients” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The treatment effect is seen within the first 2 weeks and maximal effect appears within the first 2 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Due to high drug costs, complement and FcRn inhibitors are recommended only for difficult‐to‐treat patients with severe MG not responding to standard immunosuppressive treatment. Complement and FcRn inhibitors act fast, have a proven effect with an acceptable safety profile, with a selective impact on the immune system. If costs permit and are acceptable, they should be recommended as alternative second‐line treatments.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Eculizumab: FDA-labeled indication, dosing, and pivotal trial
Eculizumab biosimilars: FDA-labeled indication
Ravulizumab: FDA-labeled indication, dosing, and pivotal trial
Zilucoplan: FDA-labeled indication, dosing, and pivotal trial
Target of approved complement inhibitors
“To date, all FDA-approved drugs in this category focus on targeting the C5 convertase enzyme.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Zilucoplan is a small macrocyclic peptide that not only binds to C5 to inhibit its cleavage, but also interferes with C5b binding to C6.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Eculizumab: REGAIN phase 3 trial in refractory AChR antibody-positive disease, 26 weeks
“Eligible patients were aged at least 18 years, with a Myasthenia Gravis-Activities of Daily Living (MG-ADL) score of 6 or more, Myasthenia Gravis Foundation of America (MGFA) class II-IV disease, vaccination against Neisseria meningitides, and previous treatment with at least two immunosuppressive therapies or one immunosuppressive therapy and chronic intravenous immunoglobulin or plasma exchange for 12 months without symptom control.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Between April 30, 2014, and Feb 19, 2016, we randomly assigned and treated 125 patients, 62 with eculizumab and 63 with placebo. The primary analysis showed no significant difference between eculizumab and placebo (least-squares mean rank 56·6 [SEM 4·5] vs 68·3 [4·5]; rank-based treatment difference -11·7, 95% CI -24·3 to 0·96; p=0·0698).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Myasthenia gravis exacerbations were reported by six (10%) patients in the eculizumab group and 15 (24%) in the placebo group. Six (10%) patients in the eculizumab group and 12 (19%) in the placebo group required rescue therapy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The use of a worst-rank analytical approach proved to be an important limitation of this study since the secondary and sensitivity analyses results were inconsistent with the primary endpoint result; further research into the role of complement is needed.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Ravulizumab: CHAMPION MG phase 3 trial, 26 weeks
“In this randomized, double-blind, placebo-controlled, multinational trial, we randomly assigned (1:1) patients with anti-AChR antibody-positive gMG to intravenous ravulizumab or placebo for 26 weeks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In total, 175 patients were enrolled. Ravulizumab significantly increased the magnitude of mean changes from baseline to week 26 versus placebo in MG-ADL (−3.1 vs. −1.4; P<0.001) and QMG (−2.8 vs. −0.8; P<0.001) total scores.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“QMG total scores improved by 5 points or more in a significantly greater proportion of ravulizumab-treated patients than of those receiving placebo (30.0% vs. 11.3%; P=0.005).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Zilucoplan: RAISE phase 3 trial, modified intention-to-treat population, 12 weeks
“Between Sept 17, 2019, and Sept 10, 2021, 239 patients were screened for the study, of whom 174 (73%) were eligible. 86 (49%) patients were randomly assigned to zilucoplan 0·3 mg/kg and 88 (51%) were assigned to placebo.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients assigned to zilucoplan showed a greater reduction in MG-ADL score from baseline to week 12, compared with those assigned to placebo (least squares mean change -4·39 [95% CI -5·28 to -3·50] vs -2·30 [-3·17 to -1·43]; least squares mean difference -2·09 [-3·24 to -0·95]; p=0·0004).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“TEAEs occurred in 66 (77%) patients in the zilucoplan group and in 62 (70%) patients in the placebo group. The most common TEAE was injection-site bruising (n=14 [16%] in the zilucoplan group and n=8 [9%] in the placebo group).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Gefurulimab: FDA-labeled mechanism, pivotal trial responder rates, and adverse reactions
Gefurulimab: PREVAIL phase 3 trial, 26 weeks
“This randomized clinical trial, PREVAIL, was a phase 3, double-blind, placebo-controlled study conducted at 113 sites in 20 countries.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of 405 patients screened, 145 were excluded; 260 met eligibility criteria and were randomized (gefurulimab, n = 131; placebo, n = 129); 249 patients completed the 26-week randomized controlled treatment period.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Least-squares mean change from baseline at week 26 for MG-ADL and QMG total scores for gefurulimab vs placebo were −4.2 vs −2.6 (treatment difference, −1.6; 95% CI, −2.4 to −0.8; P < .001) and −4.5 vs −2.4 (treatment difference, −2.1; 95% CI, −3.1 to −1.1; P < .001), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The incidence of adverse events (AEs) was similar between groups. Most common treatment-emergent AEs with gefurulimab were injection site reactions, headache, back pain, and nasopharyngitis. No meningococcal infections were reported.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Complement C5 inhibitor initiation, monotherapy, and response assessment: German-Austrian expert recommendations
“Recommendation (consensus): Add‐on therapy with C5‐I should be considered for patients with (highly) active gMG (including therapy‐refractory disease) who are positive for AChR autoantibodies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Recommendation (consensus): The use of C5‐I as monotherapy should be considered only in exceptional cases, for example, when standard immunotherapies are ineffective, associated with intolerable AEs, or contraindicated, including in the context of chronic infection or malignancy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Recommendation (strong consensus): Treatment response should be assessed after 12 weeks of C5‐I therapy, as clinical response or non‐response can usually be determined by this time and used to guide further treatment planning.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote